vaccin
viral
infect
save
million
live
protect
mani
individu
diseas
measl
rubella
mump
polio
howev
grow
need
develop
improv
vaccin
acut
infect
also
gener
therapeut
vaccin
stimul
specif
immun
respons
persist
virus
human
immunodefici
viru
human
hepat
c
viru
likewis
novel
approach
vaccin
tumor
counteract
immunosuppress
associ
cancer
need
compel
evid
cytotox
cell
crucial
player
protect
immun
respons
viral
infect
tumor
novel
vaccin
approach
thu
rigor
evalu
abil
maxim
expand
antigenspecif
cell
induc
optim
differenti
effector
cell
elicit
longlast
protect
memori
major
bottleneck
develop
new
effect
vaccin
deliveri
antigen
dendrit
cell
dc
sampl
antigen
transport
immunogen
compon
secondari
lymphoid
organ
initi
maintain
b
cell
respons
excel
capac
dc
prime
protect
antivir
cell
respons
shown
vivo
likewis
sever
preclin
studi
demonstr
effici
antitumor
immun
induc
use
adopt
transfer
dc
although
individu
adopt
transfer
antigenload
dc
feasibl
certain
extent
effici
clinic
applic
human
offtheshelf
vaccin
permit
target
deliveri
antigen
dc
vivo
becom
major
focu
vaccin
develop
consequ
descript
cell
surfac
molecul
exampl
exhibit
rather
specif
express
dc
fuel
develop
antibodybas
target
strategi
proteinbas
vaccin
gener
cell
b
cell
respons
rang
differ
antigen
howev
antigen
coupl
antibodi
major
limit
induct
cell
respons
strictli
depend
crosspresent
contrast
viral
vector
encod
immunogen
antigen
deliv
genet
cargo
directli
dc
thu
gener
antigen
peptid
infect
cell
allow
effici
load
major
histocompat
complex
mhc
class
molecul
among
current
exploit
viru
system
facilit
antigen
deliveri
dc
adenovir
lentivir
arenavir
alphavir
system
howev
major
impedi
vector
frequent
offtarget
transduct
result
antigen
present
parenchym
cell
outsid
secondari
lymphoid
organ
limit
clone
capac
insert
multipl
larg
antigen
exampl
strong
tropism
adenovir
vector
hepatocyt
genet
materi
deposit
liver
lead
gener
function
impair
cell
major
effort
thu
requir
engin
adenovir
vector
improv
specif
relev
antigenpres
cell
likewis
lentivir
vector
preferenti
infect
cell
dc
redirect
target
cell
tropism
warrant
addit
potenti
impedi
use
dnabas
viral
vector
clinic
potenti
integr
genom
materi
host
genom
coronavir
vector
display
number
featur
clearli
overcom
limit
first
replic
positivestrand
rna
virus
restrict
cytoplasm
without
dna
intermediari
make
insert
viral
sequenc
host
cell
genom
unlik
second
accumul
knowledg
attenu
coronavirus
order
provid
biosaf
vector
third
coronaviru
genom
size
kb
repres
largest
autonom
replic
rna
known
date
thu
offer
clone
capac
kb
fourth
uniqu
transcript
process
gener
subgenom
mrna
encod
four
canon
structur
protein
variou
number
accessori
protein
replac
encod
multipl
heterolog
protein
final
certainli
intrigu
cell
surfac
receptor
human
murin
coronavirus
express
human
murin
dc
respect
present
studi
describ
gener
evalu
ration
design
coronavirusbas
vector
effici
target
antigen
immunostimulatori
molecul
dc
show
murinecoronavirusbas
vector
deliv
multipl
antigen
immunostimulatori
cytokin
almost
exclus
dc
within
secondari
lymphoid
organ
immun
low
number
particl
elicit
potent
cell
respons
provid
longlast
protect
viral
challeng
moreov
singl
applic
novel
viral
vector
gener
prophylact
therapeut
immun
metastat
melanoma
induct
cytotox
lymphocyt
ctl
direct
human
melana
mela
antigen
mice
effici
humandcmedi
stimul
melaspecif
ctl
melarecombin
human
coronaviru
indic
coronavirusmedi
gene
transfer
dc
repres
versatil
approach
murin
human
immun
viral
infect
cancer
assess
immunogen
ensur
maxim
safeti
coronavirusbas
multigen
vaccin
vector
ration
design
seri
prototyp
vector
base
mous
hepat
viru
strain
fig
regard
safeti
introduc
three
basic
modif
obtain
replicationcompet
attenu
propagationdefici
mhvbase
vector
first
delet
mhv
accessori
gene
strategi
attenu
mhv
natur
host
provid
space
introduct
heterolog
gene
second
remov
nucleotid
within
replicas
geneencod
sequenc
nonstructur
protein
delet
shown
greatli
reduc
mhv
pathogen
retain
immunogen
final
delet
structur
gene
e
restrict
proper
particl
format
inde
although
replic
wildtyp
mhv
maxim
titer
occur
around
day
postinfect
vivo
replic
mhv
vector
could
detect
shown
consequ
also
mhv
vector
replic
detect
liver
brain
shown
high
safeti
profil
mhvbase
vector
illustr
fact
health
statu
differ
immunodefici
mice
affect
even
vector
appli
high
dose
see
fig
supplement
materi
order
test
coronavirusbas
vaccin
concept
develop
vaccin
provid
strong
ctl
respons
term
magnitud
longev
use
ctl
epitop
region
residu
deriv
lymphocyt
choriomening
viru
lcmv
glycoprotein
analog
peptid
deriv
human
melanamelanoma
antigen
recogn
cell
protein
fig
ctl
epitop
clone
fusion
protein
enhanc
green
fluoresc
protein
egfp
correspond
gene
design
gpegfp
clone
mhv
vectorborn
spike
membran
gene
sinc
appropri
stimul
dc
critic
gener
effici
cell
respons
henc
indispens
compon
ration
design
vaccin
insert
gene
encod
murin
granulocytemacrophag
colonystimul
factor
gmcsf
mhv
vectorborn
replicas
spike
gene
fig
propag
mhvbase
viral
vector
high
titer
produc
packag
cell
line
base
murin
cell
express
mhv
envelop
e
protein
control
tetoff
system
fig
strategi
enabl
us
restor
effici
vector
particl
format
propag
order
obtain
vector
stock
fig
assess
mhv
vector
growth
kinet
cell
express
e
protein
transduc
cell
bone
marrowderiv
dc
periton
macrophag
mhv
vector
compar
growth
kinet
wildtyp
accord
report
e
genedefici
growth
mhvbase
vector
greatli
impair
cell
fig
importantli
howev
mhv
vector
transduct
result
particl
releas
periton
macrophag
dc
demonstr
lack
e
protein
prevent
mhv
propag
primari
cell
fig
mhv
vector
elicit
signific
egfp
express
transduc
cell
periton
macrophag
fig
dc
fig
notabl
vectormedi
gmcsf
express
result
dc
activ
matur
shown
upregul
cell
fig
rapid
product
gmcsf
cell
periton
macrophag
dc
follow
exposur
cytokineencod
vector
fig
show
mhv
vector
use
simultan
express
antigen
immunostimulatori
cytokin
target
cell
determin
cellular
tropism
mhvbase
vector
transduc
splenocyt
mice
mhvgmgp
vitro
analyz
egfp
express
flow
cytometri
neither
cell
suscept
mhvgmgp
transduct
shown
wherea
antigenpres
cell
b
cell
macrophag
dc
display
green
fluoresc
indic
mhv
vectormedi
egfp
express
see
fig
supplement
materi
order
evalu
whether
target
dc
macrophag
also
achiev
vivo
inject
intraven
iv
pfu
mhvgp
mhvgmgp
mice
analyz
egfp
express
splenocyt
flow
cytometri
egfp
express
detect
mainli
dc
dc
fig
b
see
fig
supplement
materi
final
assess
effect
mhv
vectormedi
gmcsf
express
dc
stimul
activ
vivo
slightli
elev
gmcsf
level
spleen
could
observ
follow
applic
mhvgmgp
vector
fig
wherea
gmcsf
level
serum
remain
limit
detect
shown
concomit
immun
mhvgp
mhvgmmela
vector
reveal
suppli
gmcsf
tran
ie
via
mhvgmmela
vector
suffici
achiev
maxim
activ
cell
gmcsf
encod
vector
express
gpegfp
protein
mhvgmgp
maxim
immun
respons
induc
fig
furthermor
mhvgmgpinduc
gmcsf
express
alter
cellular
composit
spleen
see
fig
supplement
materi
result
support
notion
vectorencod
gmcsf
act
local
microenviron
transduc
dc
howev
vivo
transduct
mhvgp
mhvgmgp
mediat
dc
matur
upregul
fig
notabl
applic
mhvgp
vector
led
less
effici
transduct
dc
vivo
last
roughli
h
fig
suggest
gmcsf
suppli
mhv
vector
foster
dc
surviv
lesser
extent
dc
matur
therebi
potenti
antigen
present
function
infect
lcmv
character
vigor
expans
antivir
ctl
persist
protect
memori
ctl
direct
sever
epitop
two
differ
epitop
present
region
lcmv
gp
use
two
construct
day
lcmv
infect
signific
number
cell
could
detect
mhc
tetram
analysi
intracellular
cytokin
secret
ic
assay
fig
import
note
ic
record
cell
appear
process
gpegfp
transgen
mhvgp
mhvgmgp
vector
permit
preferenti
gener
cell
magnitud
compar
seen
acut
lcmv
infect
fig
gmcsfencod
mhv
vector
prove
highli
effici
induct
antivir
ctl
even
rather
low
dose
pfu
fig
sinc
intermedi
dose
pfu
mhvgmgp
led
optim
induct
ctl
use
dose
assess
whether
applic
via
differ
rout
would
influenc
induct
transgenespecif
ctl
shown
fig
rout
immun
elicit
robust
cell
respons
intraperiton
ip
subcutan
sc
intramuscular
im
iv
inject
effici
mean
applic
mhvgp
mhvgmgpinduc
cell
display
full
effector
function
peptideload
target
cell
rapidli
elimin
immun
host
see
fig
supplement
materi
mhv
vectorinduc
cell
respons
detect
day
immun
fig
importantli
could
restimul
vivo
immun
vector
fig
protect
lcmv
challeng
requir
high
level
appropri
activ
cell
order
assess
efficaci
mhv
vectorbas
immun
protect
viral
challeng
mice
immun
grade
dose
mhvgp
mhvgmgp
vector
challeng
day
later
lcmv
compar
high
level
cell
induct
fig
complet
protect
observ
mice
immun
dose
pfu
fig
remark
pfu
mhvgmgp
still
led
reduct
lcmv
titer
spleen
day
postchalleng
fig
protect
lcmv
longlast
mice
still
protect
month
follow
immun
pfu
mhvgmgp
via
iv
fig
sc
im
rout
see
fig
supplement
materi
moreov
mhvgmgp
vaccin
elicit
complet
protect
ip
challeng
lcmv
gp
recombin
vaccinia
viru
vv
fig
likewis
immun
mhvgp
provid
substanti
protect
heterolog
viral
infect
fig
import
indic
mhvbase
vaccin
even
gmcsf
encod
vector
provid
specif
protect
replic
unrel
recombin
vaccinia
viru
express
vesicular
stomat
viru
vsv
indiana
glycoprotein
vvindg
affect
fig
taken
togeth
result
reveal
mhvbase
vector
system
highli
effici
gener
protect
antivir
immun
incorpor
gmcsf
vaccin
significantli
augment
protect
capac
order
evalu
whether
mhv
vectorbas
vaccin
elicit
prophylact
therapeut
tumor
immun
resort
rapidli
grow
melanoma
model
provid
compat
lcmv
gp
system
express
minigen
cell
iv
inject
parent
cell
control
mice
result
metastat
growth
tumor
cell
lung
fig
immun
either
pfu
mhvgp
pfu
mhvgmgp
complet
block
growth
tumor
cell
wherea
metastasi
format
parent
cell
affect
fig
applic
grade
dose
mhvgp
mhvgmgp
reveal
high
efficaci
vaccin
approach
prophylact
set
ie
mhvgp
pfu
mhvgmgp
suffici
prevent
growth
melanoma
cell
fig
longlast
memori
respons
provid
signific
protect
challeng
gener
follow
mhvgmgp
immun
fig
moreov
potent
cell
respons
elicit
mhvgmgp
immun
mediat
therapeut
tumor
immun
fig
ie
tumor
burden
lung
mice
significantli
reduc
even
vaccin
appli
tumor
start
form
metastat
nodul
indic
cell
respons
elicit
novel
mhv
vector
exert
forc
antitumor
activ
substanti
find
mhv
vector
induc
potent
relev
antitumor
cell
respons
employ
human
system
immun
respons
analog
peptid
monitor
mice
mice
immun
iv
either
pfu
pfu
mhvgmmela
melaspecif
cell
respons
record
use
tetram
analysi
ic
shown
fig
vector
elicit
substanti
cell
respons
time
cours
experi
follow
iv
applic
mhvgmmela
reveal
strong
global
expans
cell
nearli
massiv
expans
melaspecif
cell
cell
per
spleen
tetram
posit
cell
per
spleen
secret
gamma
interferon
fig
melaspecif
cell
popul
show
typic
contract
day
stabl
memori
popul
establish
day
postimmun
fig
acut
phase
follow
mhvgmgp
immun
melaspecif
cell
downregul
fig
expect
memori
cell
reacquir
express
indic
establish
central
memori
cell
popul
overal
result
underlin
coronavirusbas
vaccin
approach
particularli
combin
immunostimulatori
cytokin
gmcsf
provid
effici
mean
induct
cell
respons
human
tumor
antigen
human
coronavirusbas
vector
permit
specif
transfer
multipl
gene
dc
receptor
human
aminopeptidas
n
hapn
express
human
dc
furthermor
demonstr
previous
vector
transduc
immatur
matur
human
dc
report
gene
firefli
luciferas
gene
assess
whether
deliveri
analog
peptid
human
dc
would
specif
stimul
human
melaspecif
cell
end
gener
two
recombin
human
coronavirus
design
replac
accessori
gene
gene
fusion
protein
respect
fig
shown
fig
egfp
express
readili
detect
human
immatur
matur
dc
infect
time
cours
analysi
human
matur
dc
infect
reveal
high
level
egfp
express
reach
earli
h
postinfect
see
fig
supplement
materi
final
matur
dc
infect
employ
stimul
human
cell
shown
fig
observ
effici
stimul
tumorspecif
cell
indic
pronounc
tropism
human
dc
repres
particularli
promis
tool
genet
deliv
antigen
human
antigenpres
cell
studi
describ
novel
vaccin
approach
facilit
deliveri
viral
tumor
antigen
dc
vivo
concomit
via
cytokin
achiev
target
transduct
viral
vector
singl
immun
mhvbase
particl
suffici
elicit
vigor
expans
optim
differenti
cell
ii
protect
longlast
antivir
immun
iii
prophylact
therapeut
tumor
immun
moreov
highli
effici
antigen
deliveri
human
dc
recombin
specif
stimul
human
cell
reveal
approach
except
well
suit
translat
human
vaccin
studi
target
antigen
dc
vivo
achiev
sever
mean
use
viral
vector
appear
superior
strategi
elicit
innat
activ
immun
system
optim
induct
cell
howev
mani
viru
vector
system
still
limit
abil
induc
broad
longlast
immun
respons
exampl
recombin
adenovirus
studi
intens
vaccin
candid
mainli
produc
high
titer
nevertheless
high
dose
recombin
adenoviru
vector
appli
induc
immun
respons
probabl
target
antigen
mainli
nonlymphoid
organ
liver
contrast
viral
vector
base
dna
virus
positivestrand
rna
virusbas
vector
replic
cytoplasm
consid
safe
vector
safeti
well
document
vector
base
wide
use
vaccin
strain
polioviru
viruslik
particl
vlp
contain
replicon
rna
devoid
structur
gene
note
applic
mhvbase
vector
describ
studi
alway
well
toler
result
sign
diseas
advers
side
effect
irrespect
dosag
rout
mhvbase
vector
applic
even
immunodefici
mous
strain
final
noteworthi
although
rna
virusbas
vector
abl
target
dc
clone
capac
sharp
contrast
coronavirusbas
vector
gener
restrict
express
multipl
antigen
andor
immunostimulatori
cytokin
limit
novel
coronavirusbas
vaccin
platform
describ
display
high
immunogen
like
pronounc
tropism
mhvbase
vector
dc
macrophag
within
secondari
lymphoid
organ
guarante
effici
activ
primari
cell
respons
vivo
imag
studi
shown
dc
subcapsular
sinu
lymph
node
effici
present
viral
antigen
cell
likewis
macrophag
locat
abl
collect
viral
antigen
lymph
present
antigen
follicular
b
cell
moreov
recent
studi
laboratori
reveal
type
ifnmedi
protect
dc
macrophag
cytopath
effect
mhv
infect
essenti
buy
time
mount
protect
cell
respons
remain
resolv
presenc
mhv
receptor
dc
preferenti
infect
relev
antigenpres
cell
within
secondari
lymphoid
organ
adapt
coronavirusbas
vector
human
system
essenti
paramet
clarifi
ie
receptor
express
mainli
monocyt
dc
within
secondari
lymphoid
organ
recombin
effici
target
human
dc
irrespect
matur
statu
import
add
one
least
four
human
coronavirus
transmit
via
mucos
surfac
associ
mild
upper
respiratori
tract
infect
common
cold
furthermor
low
pathogen
potenti
corrobor
fact
passag
volunt
without
seriou
side
effect
featur
togeth
pronounc
dctarget
capabl
demonstr
report
encourag
develop
coronavirusbas
vector
human
use
second
major
advantag
coronavirusbas
vaccin
strategi
larg
clone
capac
vector
offer
possibl
incorpor
immunostimulatori
cytokin
gmcsfencod
mhv
vector
led
strong
product
cytokin
macrophag
dc
vitro
interestingli
gmcsf
express
vivo
appear
larg
restrict
local
transduc
cell
gross
differ
gmcsf
level
spleen
serum
observ
mhvgmgp
vector
immun
like
gmcsfinduc
chang
within
microenviron
transduc
macrophag
dc
decis
optim
induct
effector
memori
cell
respons
inde
optim
stimul
express
costimulatori
molecul
antigenpres
cell
togeth
suffici
innat
immun
stimul
determin
primari
expans
mainten
antivir
cell
accordingli
nontcr
signal
signal
consid
key
compon
ration
design
vaccin
lack
optim
compos
stimuli
vectorbas
vaccin
like
requir
elabor
primeboost
immun
regim
recent
shown
combin
adenovirusmva
vaccin
approach
andor
substanti
increas
vector
dose
achiev
efficaci
exampl
vaccin
latest
version
dcadapt
lentiviru
vector
applic
particl
requir
achiev
signific
expans
ovalbuminspecif
cell
mice
conclus
provid
versatil
vaccin
platform
base
coronavirus
achiev
effici
gener
protect
immun
shown
longlast
memori
viral
challeng
induct
prophylact
therapeut
tumor
immun
biolog
coronavirus
ration
modif
viral
rna
vector
harbor
signific
potenti
futur
develop
experi
perform
accord
feder
kanton
guidelin
permiss
number
follow
review
approv
kanton
veterinari
offic
st
gallen
switzerland
mice
obtain
charl
river
laboratori
sulzfeld
germani
mice
kindli
suppli
f
lemonni
pasteur
institut
pari
franc
mice
maintain
individu
ventil
cage
use
week
age
cell
purchas
european
collect
cell
cultur
cell
obtain
r
zinkernagel
univers
switzerland
cell
kind
gift
j
f
smith
imperi
colleg
london
london
unit
kingdom
cell
kind
gift
g
sawicki
medic
univers
ohio
toledo
oh
cell
kind
gift
v
lohmann
univers
heidelberg
germani
lcmv
strain
obtain
r
zinkernagel
switzerland
recombin
vaccinia
viru
express
lcmv
glycoprotein
origin
obtain
b
h
bishop
univers
oxford
unit
kingdom
recombin
vaccinia
viru
express
vesicular
stomat
viru
indiana
glycoprotein
vvindg
origin
obtain
b
moss
nation
institut
health
bethesda
md
titrat
determin
antivir
protect
assay
perform
describ
previous
detail
found
text
supplement
materi
genom
rna
recombin
mhvbase
vector
recombin
hcov
produc
clone
cdna
use
purifi
vaccinia
viru
dna
templat
vitro
transcript
describ
previous
detail
descript
clone
step
sequenc
inform
product
recombin
coronaviru
particl
found
text
supplement
materi
gener
bone
marrowderiv
dc
flow
cytometr
analysi
perform
describ
previous
inform
procedur
found
text
supplement
materi
immunofluoresc
analysi
viral
replic
cell
periton
macrophag
seed
slide
chamber
transduc
mhvgp
mhvgmgp
moi
time
point
indic
fig
slide
aceton
fix
block
fcblock
antibodi
stain
antiegfp
alexa
biolegend
imag
acquir
use
leica
dmra
microscop
process
use
adob
photoshop
adob
system
peptidespecif
cell
ex
vivo
product
tumor
necrosi
factor
alpha
determin
tetram
stain
intracellular
cytokin
stain
perform
describ
previous
detail
inform
procedur
found
text
supplement
materi
melanoma
cell
express
lcmv
epitop
parent
cell
kindli
provid
h
pircher
univers
freiburg
germani
inform
tumor
protect
assay
found
text
supplement
materi
dc
gener
monocyt
isol
peripher
blood
mononuclear
cell
describ
previous
matur
dc
infect
melaegfprecombin
gpegfprecombin
incub
melaspecif
cell
clone
respond
cell
detail
vitro
human
cell
activ
transduc
human
dc
found
text
supplement
materi
statist
analys
perform
prism
graphpad
softwar
inc
data
analyz
nonpair
student
test
assumpt
valu
follow
gaussian
distribut
p
valu
consid
signific
